Bioatla presenting phase 1 evalstotug clinical trial data demonstrating clinical benefit at the upcoming 2024 american society of clinical oncology (asco) annual meeting

Multiple refractory pd1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug

BCAB Ratings Summary

BCAB Quant Ranking